Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

ClinicalTrials.gov ID: NCT06582017

Public ClinicalTrials.gov record NCT06582017. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Study identification

NCT ID: NCT06582017
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Nammi Therapeutics Inc; Industry
Enrollment: 100 participants

Conditions and interventions

Conditions

Interventions

QXL138AM Injection every 2 weeks by IV Infusion Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 27, 2024
Primary completion: Dec 30, 2027
Completion: May 29, 2028
Last update posted: Apr 12, 2026

2024 – 2028

United States locations

U.S. sites: 10
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Southern California	Los Angeles	California	90033	Recruiting
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer	Los Angeles	California	90048	Recruiting
Cedars-Sanai Medical Center	Los Angeles	California	90048	Recruiting
Hoag Memorial Hospital Presbyterian	Newport	California	92663	Recruiting
Sarah Cannon Research Institute - Denver DDU	Denver	Colorado	80218	Recruiting
Emory University - Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
New York Cancer & Blood Specialists	New York	New York	11967	Recruiting
University of Rochester - Wilmot Cancer Institute	Rochester	New York	14642	Recruiting
START San Antonio	San Antonio	Texas	78229	Recruiting
Froedtert Hospital & the Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06582017, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06582017 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →